NEXEL

offers advanced hiPSC-derived cells for drug discovery, disease modeling, and regenerative medicine

Nexel Logo

Why Choose hiPSC-Derived Cells?

  • High-Quality Differentiation
  • Versatile Applications
  • Scalable Production
  • Cutting-Edge iPSC Technology

Product Features

  • Wide Range of Cell Types: We offer a diverse array of hiPSC-derived cell types, including cardiomyocytes, hepatocytes, and neural cells, to meet the specific needs of your research.
  • High Purity and Viability: Our cells are characterized by high purity and viability, ensuring optimal performance in your experiments.
  • Customizable Solutions: We provide customized cell solutions tailored to your specific research requirements

Overview of our products for NEXEL.

pelobiotech-cells.jpg
Cardiosight®-S - (Nexel) Cells

Applications

  • Drug Discovery: Accelerate the identification and development of new therapeutic compounds.
  • Disease Modeling: Create accurate models of human diseases for better understanding and treatment.
  • Regenerative Medicine: Support the development of cell-based therapies for tissue repair and regeneration.
  • Toxicology Studies: Assess the safety and efficacy of new drugs and chemicals.

Benefits

  • Enhanced Research Accuracy: The hiPSC-derived cells provide a more physiologically relevant model, improving the accuracy of your research findings.
  • Reduced Time and Cost: Streamline your research process with high-quality, ready-to-use cells, reducing the time and cost associated with cell culture and differentiation.
  • Ethically Sourced: The cells are derived from ethically sourced human iPSCs, ensuring compliance with ethical standards and regulations.

Frequently Asked Questions

What types of hiPSC-derived cells are available from NEXEL?

  • a variety of hiPSC-derived cell types, including cardiomyocytes, hepatocytes, and neural cells, to support diverse research applications.

How do hiPSC-derived cells differ from other cell products?

    • The are produced using Nexel's proprietary iPSC technology, ensuring high purity, viability, and consistency, making them ideal for advanced research applications.

 

References

2024

  • Modeling acute myocardial infarction and cardiac fibrosis using human induced pluripotent stem cell-derived multi-cellular heart organoids. Cell Death & Disease. DOI: 10.1038/s41419-024-06703-9

2023

  • Generation of multilineage liver organoids with luminal vasculature and bile ducts from human pluripotent stem cells via modulation of Notch signaling. Stem Cell Research & Therapy. DOI: 10.1186/s13287-023-03235-5

2022

  • Development of human pluripotent stem cell-derived hepatic organoids as an alternative model for drug safety assessment. Biomaterials.
  • Three-dimensional cardiac organoid formation accelerates the functional maturation of human induced pluripotent stem cell-derived cardiomyocytes. Organoid.
  • Cyclic Stretching Induces Maturation of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes through Nuclear-Mechanotransduction. TERM.
  • Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCs. Biomaterials.

2021

  • Truncated Milk Fat Globule-EGF-Like Factor 8 Ameliorates Liver Fibrosis via Inhibition of Integrin-TGFβ Receptor Interaction. Biomedicines. DOI: 10.3390/biomedicines9111529
  • Evaluation of cardiac safety using human pluripotent stem cell-derived cardiomyocytes. KALAS.
  • Trends in the global organoid technology and industry: from organogenesis in a dish to the commercialization of organoids. Organoid. DOI: 10.51335/organoid.2021.1.e11
  • Modulations of Cardiac Functions and Pathogenesis by Reactive Oxygen Species and Natural Antioxidants. Antioxidants. DOI: 10.3390/antiox10050760
  • Human pluripotent stem-cell-derived alveolarorganoids for modeling pulmonary fibrosis and drug testing. Cell Death Discovery. DOI: 10.1038/s41420-021-00439-7

2020

  • Alterations of Ca2+ signaling and Ca2+ release sites in cultured ventricular myocytes with intact internal Ca2+ storage. BBRC. DOI: 10.1016/j.bbrc.2020.04.059
  • Human Embryonic Stem Cell-Derived Wilson’s Disease Model for Screening Drug Efficacy. MDPI Cells. DOI: 10.3390/cells9040872

2019

2018

  • Rho-associated kinase inhibitor enhances the culture condition of isolated mouse salivary gland cells in vitro. Tissue and Cell. DOI: 10.1016/j.tice.2018.07.002

2017

2016

  • Enhancing a Wnt-Telomere Feedback Loop Restores Intestinal Stem Cell Function in a Human Organotypic Model of Dyskeratosis Congenita. Cell Stem Cell. DOI: 10.1016/j.stem.2016.05.024

2015

2014

  • Mitochondrial Induced and Self‒Monitored Intrinsic Apoptosis by Antitumor Theranostic Prodrug: In Vivo Imaging and Precise Cancer Treatment . JACS. DOI: 10..1021/ja510421q

2013

  • Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells . Cancer Cell. DOI: 10..1016/j.ccr..04..008

2012

  • Direct and Indirect Contribution of Human Embryonic Stem Cell‒Derived Hepatocyte‒Like cells to Liver Repair in Mice DOI: . Gastroenterology. DOI: .1053/j.gastro..11..030

We are here for you.

Call us, write to us or make an appointment for a personal conversation
with us on site. Please do not hesitate to call, we love to be at
your service anytime.

PELOBIOTECH GmbH
Behringstrasse 10
82152 Germany

Phone +49 (0) 89 517 286 59 0
Mail info@pelobiotech.com

*Mandatory field

I have taken note of the privacy policy. I agree that my details will be stored permanently for contacting me and for queries. Note: You can revoke your consent at any time for the future by email to info@pelobiotech.com.